Randomized Study of Single Instillation of Epirubicin for Superficial Bladder Carcinoma: Long-Term Clinical Outcomes

REFERENCES

• Liu B., Zhang Y. The role of epirubicin in treatment and prevention recurrence of bladder carcinoma. China Oncol. 1998; 8: 232–234
   Google Scholar
• Zhang Y., Zhang Z., Tang Y., et al. Single and consecutive instillation of epirubicin and mitomicin C for prevention recurrence of bladder carcinoma. China Oncol. 2000; 10: 211–214
   Google Scholar
• Liu B., Zhang Y., Wang Z., et al. Single dose instillation of epirubicin for prevention recurrence of bladder carcinoma. Chinese Surg. 2002; 40: 112–115, [CSA]
   PubMedGoogle Scholar
• Hara I., Miyake H., Takechi Y., et al. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder. Int. J. Urol. 2003; 10: 19–24, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mohanty N. K., Malhotra V., Nayak R. L., Arora R. P. Combined low-dose intravesical immunotherapy (BCG + interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up. J. Chemother. 2002; 14: 194–197, [CSA]
   PubMed Web of Science ®Google Scholar
• Hausladen D. A., Wheeler M. A., Altieri D. C., et al. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survival levels and outcome. J. Urol. 2003; 170: 230–234, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Solsona E., Iborra I, Ricós J. V., Monrós L., Casanova J., Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J. Urol. 1999; 161: 1120–1123, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Okamura K., Kinukawa T., Tsmura Y., et al. A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Naoya University Urological Oncology Group. Eur. Urol. 1998; 33: 285–288, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Maekawa S., Suzuki H., Ohkubo K., Okada T., Maeda H., Ogura K., Arai Y. Continuous intravesical instillation of epirubicin immediately after transurethral resection of superficial bladder cancer: a prospective controlled study. Hiyokika kiyo 2000; 46: 301–306, [CSA]
   PubMedGoogle Scholar
• Kondo T., Onitsuka S., Ryoji O., et al. Analysis of prognostic factors related to primary superficial bladder cancer tumor recurence in prophylactic intravesical epirubicin therapy. Int. J. Urol. 1999; 6: 178–183, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• de Reijke T. M., Kurth K. H., Sylvester R. J., Hall R. R., Brausi M., et al. European Organization for the Research and Treatment of Cancer-Genito-Urinary Group. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer–Genito-Urinary Group Phase IIITrial (30906). J. Urol. 2005; 173(2)405–409, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nomata K., Noguchi M., Kanetake H., Tsuda N., Hayashi M., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment. Cancer. Chemother. Pharm. 2002; 50(4)266–270, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rajala P., Kaasinen E., Raitanen M., Liukkonen T., Rintala E. Finnbladder Group. Perioperative single dose instillation of epirubicin or interferon-a after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study-Finnbladder III long-term results. J. Urol. 2002; 168: 981–985, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Parmar M. K.B., Freedman L. S., Hargreave T. B., Tolley D. A. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council subgroup on superficial bladder cancer (Urological Cancer Working Party). J. Urol. 1989; 142: 284–288, [CSA]
   PubMed Web of Science ®Google Scholar
• Lamm D. L., Blumenstein B. A., Crawford E. D., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N. Engl. J. Med. 1991; 325: 1205–1209, [CSA]
   PubMed Web of Science ®Google Scholar
• Witjes J. A., Meijden A. P., Sylvester L. C., Debruyne F. M., van Aubel A., et al. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 1998; 52: 403–410, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kurth K. H., Bouffioux C., Sylvester R., van der Meijden A. P., Oosterlinck W., Brausi M. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur. Urol. 2000; 37(Suppl 3)1–9, [CSA]
   PubMedGoogle Scholar
• Oosterlinck W., Kurth K. H., Schröder F., Bultinck J., Hammond B., Sylvester R. Members of the European Organization for Research and Treatment of Cancer Genitourinary Group. A prospective European organization for research and treatment of cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J. Urol. 1993; 149: 749–752, [CSA]
   PubMed Web of Science ®Google Scholar
• Tolley D. A., Parmar M. K.B., Grigor K. M., Lallemand G. Medical Research Council Superficial Bladder Cancer Working Party. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J. Urol. 1996; 155: 1233–1238, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ali-El-Dein B., Nabeeh A., El-Baz M., Shamaa S., Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: prospective, randomized controlled study. Br. J. Urol. 1997; 79: 731–735, [CSA]
   PubMedGoogle Scholar
• Rajala P., Liukkonen T., Raitanen M., et al. Transurethral resection with perioperative instillation of interferon- or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study-Finnbladder III. J. Urol. 1999; 161: 1133–1136, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar